BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the relative efficacy and safety of bevacizumab versus ranibizumab for the treatment of the neovascular form of age-related macular degeneration. METHODS: A comprehensive literature search using the Cochrane Methodology Register to identify randomized controlled trials comparing bevacizumab with ranibizumab in patients with neovascular age-related macular degeneration. Efficacy estimates were determined by comparing weighted mean differences in the change of best-corrected visual acuity and central macular thickness from baseline. Safety estimates were determined by calculating the risk ratio for rates of death, arteriothrombotic events, venous thrombotic events, and at least 1 serious systemic adverse event. Statistical analysis was performed using the RevMan 5.1 software. RESULTS: A total of 6 randomized controlled trials were selected for this meta-analysis, including 2,612 patients (1,292 patients in the bevacizumab group and 1,320 patients in the ranibizumab group). There were no significant differences between bevacizumab and ranibizumab in best-corrected visual acuity mean change at 1 year or 2 years (weighted mean difference = -0.40, 95% confidence interval [CI], -1.48 to 0.69, P = 0.47 and weighted mean difference = -1.16, 95% CI, -2.82 to 0.51, P = 0.17, respectively). Ranibizumab was found to be more efficacious in reducing central macular thickness at 1 year (weighted mean difference = 4.35, 95% CI, 0.92-7.78, P = 0.01). The pooled risk ratios comparing the rates of serious systemic adverse events at 1 year and 2 years were slightly in favor of ranibizumab (risk ratio = 1.24, 95% CI, 1.04-1.48, P = 0.02 and risk ratio = 1.20, 95% CI, 1.05-1.37, P = 0.008, respectively), whereas the rates of death, arteriothrombotic events, and venous thrombotic events did not differ statistically. CONCLUSION: Bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. Ranibizumab tended to have a better anatomical outcome. There were no differences between drugs in rates of death, arteriothrombotic events or venous thrombotic events, and differences in rates of serious systemic adverse events that require further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab was first approved for use in the treatment of colorectal cancer, however it is used off label for intraocular use. It is repackaged by compounding pharmacies for intravitreal injection, and has been shown to have similar efficacy and safety profile when compared to ranibizumab [9].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [9]
In the citing paper
“It is repackaged by compounding pharmacies for intravitreal injection, and has been shown to have similar efficacy and safety profile when compared to ranibizumab [9].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [9]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“05 was considered representative of significant statistical heterogeneity).(17) If there was heterogeneity between studies, a random-effects model was applied to the data.”
MethodBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“05 was considered representative of significant statistical publication bias).(18,19)”
BackgroundOperating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · cited 1×
“05 was considered representative of significant statistical publication bias).(18,19)”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093 · cited 4×
“Although the neovascular form of AMD accounts for only 20% of the cases with AMD, it is responsible for almost 90% of severe visual loss resulting from AMD.(2) It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the formation of choroidal neovascularization in AMD.”
BackgroundInfluentialRanibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781 · cited 2×
“The IVAN study also conducted a metaanalysis of key outcomes from the CATT and IVAN trials, indicating that bevacizumab was noninferior to ranibizumab.(13,14) To the best of our knowledge, only one study attempted a meta-analysis of randomized controlled trials (RCTs) comparing the safety profiles of bevacizumab with…”
MethodResult
Research works printed but not linked: 3
- Jadad, 1996, Carroll D, et al.., Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials, 17, 1
- Beaumont, 2011, Bevacizumab: not as good with more adverse reactions Clin Experiment O, phthalmol, 39, 588
- Lim, 2011, Mitchell P, et al.., Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned Am J Ophthalmol, 152, 329
Cited by
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity
Morin, J., Luu, T. M., Superstein, R., Ospina, L. H., Lefebvre, F., Simard, M., Shah, V. S., Shah, P. S., Kelly, E., & the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators (2016) · PEDIATRICS · doi:10.1542/peds.2015-3218 · Cited by 302
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Rufai, S. R., Almuhtaseb, H., Paul, R. M., Stuart, B. L., Kendrick, T., Lee, H., & Lotery, A. J. (2017) · Eye · doi:10.1038/eye.2017.67 · Cited by 64
Nguyen, C. L., Oh, L. J., Wong, E. H., Wei, J., & Chilov, M. N. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0785-3 · Cited by 63
“The methodology used for this meta-analysis was adapted from previous meta-analyses for consistency [4, 20].”
Method
Metadata
- Authors
- Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y.
- Affiliations
- Xiamen University (CN)
- University of South Florida (US)
- Quzhou City People's Hospital (CN)
- Corresponding author
- Chen, Guohai
- Jiang, Fangzheng
- Mao, Sihong
- Tong, Yuhua
- Venue
- Retina
- Published
- 2015-02
- Volume
- 35
- Issue
- 2
- Pages
- 187-193
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2036703870
- Cited by
- 36
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 5
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- bevacizumab, ranibizumab, neovascular age-related macular degeneration, anti-VEGF therapy, best-corrected visual acuity, central macular thickness, treatment safety and efficacy comparison, intravitreal injection
- MeSH terms
- Bevacizumab, Ranibizumab, Humans, Visual Acuity, Randomized Controlled Trials as Topic, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1097/iae.0000000000000301
- The paper
- Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y. (2015). BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials. Retina. https://doi.org/10.1097/iae.0000000000000301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.